Role of Prdx6 in the activation of NADPH oxidase
Prdx6 在 NADPH 氧化酶激活中的作用
基本信息
- 批准号:8789380
- 负责人:
- 金额:$ 52.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Lung InjuryAgonistAlveolar MacrophagesAngiotensin IIApplications GrantsBindingBiochemical PathwayCell membraneCell-Free SystemCellsConcanavalin ACysteineDataDevelopmentEndothelial CellsEndotheliumFamilyGenerationsGoalsHealthHumanIn VitroInflammationInflammatoryInjuryIschemiaKineticsKnock-outKnockout MiceLungLysophosphatidylcholinesMeasurementMediatingMembraneMethodsModelingMolecularMultienzyme ComplexesMusNADPH OxidaseNull LymphocytesOxidantsOxidative StressPathway interactionsPeroxidasesPhospholipase A2PhospholipidsPhosphorylationPhosphotransferasesPhysiologicalProductionProteinase 3ProteinsPublicationsReactive Oxygen SpeciesRecombinant ProteinsReperfusion TherapyRoleSignal TransductionStimulusTestingTissuescell injurycell typein vivoinflammatory lung diseaseinhibitor/antagonistinsightlung injurylung ischemiamemberneutrophil cytosol factor 67Knovelperoxiredoxinphospholipase A2 inhibitorpreventprotein protein interactionreconstitutionresponse
项目摘要
DESCRIPTION (provided by applicant): The goal of this proposal is to evaluate a novel role for Prdx6 in the activation of NADPH oxidase (NOX2). Our hypothesis is that in response to a stimulus, Prdx6 is phosphorylated and translocates to the plasma membrane where it generates lysophosphatidylcholine (lysoPC) resulting in activation of NOX2. This hypothesis will be tested by 3 (of 5) specific aims. Specific Aim 1 will evaluate the effect of Prdx6 "knockout" on agonist-induced activation of NOX2 in alveolar macrophages (AM) and pulmonary microvascular endothelial cells in culture and in the isolated perfused lung. Activation is determined by translocation of cytosolic components to the membrane and generation of reactive oxygen species (ROS). Specific Aim 2 will evaluate the mechanism for Prdx6-mediated activation of NOX2; we propose that generation of lysoPC by the phospholipase A2 (PLA2) activity of Prdx6 is responsible. Specific Aim 3 will evaluate the requirement for Prdx6 phosphorylation in its translocation to the plasma membrane and NOX2 activation. We further propose that binding of one of the cytosolic components (p67phox) to Prdx6 inhibits its PLA2 activity and abrogates the NOX2-activation signal. Specific Aim 4 will study the interaction of Prdx6 with p67phox in intact cells and with recombinant protein in vitro with specific focus on the PLA2 activity of Prdx6 and the kinetics of the protein-protein interaction. Finally, Specific Aim 5 will investigate the effect of a Prdx6 PLA2 inhibitor, MJ33, in preventing oxidative stress with ischemia in the isolated lung and acute lung injury with ischemia-reperfusion in vivo. We postulate that this agent will maintain the protective peroxidase activity of Prdx6 while inhibiting the activation of NOX2. The proposed studies will provide a coordinated effort to investigate this novel role of Prdx6 and will provide the basic insights for development of new methods to inhibit the activation of the NOX2 enzyme complex and ameliorate ROS-mediated lung injury.
描述(由申请人提供):本提案的目的是评估Prdx6在NADPH氧化酶(NOX2)激活中的新作用。我们的假设是,在对刺激的反应中,Prdx6被磷酸化并易位到质膜,在那里它产生溶血磷脂酰胆碱(lysoPC),导致NOX2的激活。这个假设将通过3个(或5个)具体目标来检验。特异性目的1将评估Prdx6“敲除”对激动剂诱导的肺泡巨噬细胞(AM)和肺微血管内皮细胞中NOX2在培养和离体灌注肺中的激活作用。激活是由细胞质成分向膜的易位和活性氧(ROS)的产生决定的。特异性目的2将评估prdx6介导的NOX2激活的机制;我们提出,通过Prdx6的磷脂酶A2 (PLA2)活性产生lysoPC是负责任的。特异性Aim 3将评估Prdx6转运到质膜和NOX2激活过程中磷酸化的必要性。我们进一步提出其中一种细胞质成分(p67phox)与Prdx6结合可抑制其PLA2活性并消除nox2激活信号。Specific Aim 4将在完整细胞中研究Prdx6与p67phox的相互作用,并在体外研究Prdx6与重组蛋白的相互作用,重点研究Prdx6的PLA2活性以及蛋白-蛋白相互作用的动力学。最后,Specific Aim 5将研究Prdx6 PLA2抑制剂MJ33在体内对离体肺缺血氧化应激和急性肺损伤缺血再灌注的预防作用。我们假设该制剂将维持Prdx6的保护性过氧化物酶活性,同时抑制NOX2的激活。拟议的研究将为研究Prdx6的新作用提供协调的努力,并将为开发抑制NOX2酶复合物激活和改善ros介导的肺损伤的新方法提供基本见解。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Response to letter by Dr. M. S. A. Mohamed (Antagonizing reactive oxygen species during lung perfusion).
对 M. S. A. Mohamed 博士的信件的回应(在肺灌注过程中拮抗活性氧)。
- DOI:10.1152/ajplung.00310.2014
- 发表时间:2014
- 期刊:
- 影响因子:0
- 作者:Chatterjee,Shampa;Nieman,GaryF;Christie,JasonD;Fisher,AronB
- 通讯作者:Fisher,AronB
Functional interaction of glutathione S-transferase pi and peroxiredoxin 6 in intact cells.
完整细胞中谷胱甘肽 S-转移酶 pi 和过氧化还原蛋白 6 的功能相互作用。
- DOI:10.1016/j.biocel.2012.11.005
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Zhou,Suiping;Lien,Yu-Chin;Shuvaeva,Tea;DeBolt,Kristine;Feinstein,SheldonI;Fisher,AronB
- 通讯作者:Fisher,AronB
Antioxidants in the intensive care unit.
重症监护室的抗氧化剂。
- DOI:10.1164/rccm.201401-0156le
- 发表时间:2014
- 期刊:
- 影响因子:24.7
- 作者:Fisher,AronB;Forman,HenryJay
- 通讯作者:Forman,HenryJay
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aron B. FISHER其他文献
Aron B. FISHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aron B. FISHER', 18)}}的其他基金
Role of Prdx6 in the activation of NADPH oxidase
Prdx6 在 NADPH 氧化酶激活中的作用
- 批准号:
8212032 - 财政年份:2011
- 资助金额:
$ 52.41万 - 项目类别:
Role of Prdx6 in the activation of NADPH oxidase
Prdx6 在 NADPH 氧化酶激活中的作用
- 批准号:
8432046 - 财政年份:2011
- 资助金额:
$ 52.41万 - 项目类别:
Role of Prdx6 in the activation of NADPH oxidase
Prdx6 在 NADPH 氧化酶激活中的作用
- 批准号:
8024096 - 财政年份:2011
- 资助金额:
$ 52.41万 - 项目类别:
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell Membranes
过氧化还原蛋白 6 在过氧化细胞膜修复中的作用
- 批准号:
9237295 - 财政年份:2010
- 资助金额:
$ 52.41万 - 项目类别:
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell Membranes
过氧化还原蛋白 6 在过氧化细胞膜修复中的作用
- 批准号:
8816964 - 财政年份:2010
- 资助金额:
$ 52.41万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 52.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 52.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 52.41万 - 项目类别:














{{item.name}}会员




